SNP 6.0 array–based lesion cutoffs and del17p/del11q or TP53 exon 2-10 mutation status and OS in CLL (bivariate analysis; Kaplan-Meier plots). Previously untreated patient group analyzed from trial enrollment (A-C) del17p/del11q status and various SNP 6.0 array–based lesion cutoffs and (D-F) TP53 exon 2-10 mutation status and various SNP 6.0 array–based lesion cutoffs.